MIGRAINE
2 to 8 migraines a month?
Still struggling to manage them? Don’t settle. Help us learn about a new investigational approach to treatment. Contact our study team and find out if you qualify for a new clinical research study called BHV-3500.
Contact details:
Coastal Clinical Research, Inc.
100 Memorial Hospital Drive Annex Building Suite 3-B, Mobile, AL, 36608
DO YOU SUFFER FROM MIGRAINES?
A clinical research study is being conducted to learn if an investigational drug may help prevent migraines
QUALIFIED PARTICIPANTS MUST:
- Be between the ages of 18 and 80
- Have 4-14 migraine days per month
- Have at least a 1 year history of migraines
QUALIFIED PARTICIPANTS MAY RECEIVE:
- Investigational drug & study examinations at no cost
- Compensation for time & travel
Migraine Study
Migraine Study
Migraine Study
HOW ARE YOU DEALING WITH migraines?
DOES YOUR CHILD SUFFER FROM MIGRAINE ATTACKS?
If your child is between the ages of 6 and 17 and suffers from migraine attacks they may qualify for this study! Study treatment is at no cost to the patient.
CENTRAL STATES RESEARCH
IT’S HARD ENOUGH COPING WITH RECURRENT MIGRAINE ATTACKS. ADD SUFFERING FROM DEPRESSION AND IT’S NEARLY IMPOSSIBLE TO FUNCTION.
We’re researching a marketed medication to see if it can prevent migraine in people with major depressive disorder. Join us.
The UNITE study is evaluating an investigational drug called fremanezumab in adults with migraine and major depressive disorder (MDD). Fremanezumab is currently approved in several countries for the prevention of migraine, but it is not approved for treating MDD.
You may qualify to participate if you:
* Are 18 to 70 years of age
* Experience migraines, and:
- the migraines started before age 50
- have 4 or more migraine days within a month
* Are either not using or using no more than 1 migraine preventive medication (e.g., topiramate)
* Are diagnosed with moderate or severe Major Depressive Disorder for at least the past year. If taking medication for MDD, you must be on a stable dose for the last 2 months.
Other criteria will be reviewed to determine if you qualify for this study. Participation in the study will last approximately 7 months and will require about 6 visits to the research clinic. The study drug, clinic visits, laboratory tests, and procedures that are part of the study will be provided at no cost. You may also be compensated for your study-related travel expenses.
For more information, please contact:
Oregon Center for Clinical Investigations, Inc. - (Portland, OR)
If you have Migraine and are interested in this research study, enter your information here.
Are you suffering from MIGRAINES?
A clinical research studyis being conducted for adults who have had migraines for at least a year.
QUALIFIED PARTICIPANTS MAY RECEIVE:
- Compensation for time and travel
- Study-related care at no cost
Are you suffering from MIGRAINES?
A clinical research study is being conducted for adults who have had migraines for at least a year.
QUALIFIED PARTICIPANTS MAY RECEIVE:
- Compensation for time and travel
- Study-related care at no cost
Do You Suffer From Migraines?
If you have betweeen 2-8 migraines per month, you could participate in a study to help us learn about a new investigational medication being tested for the acute treatment of migraines.
See if you Qualify
Migraine Long Term Safety Study
Biohaven Pharmaceuticals is studying the safety and tolerability of a new drug called zavagepant intranasal administration, for the acute treatment of migraine. If you are at least 18 years of age you may qualify.
Contact one of our research sites and find out if you qualify for a clinical research study. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided
Who is this study for?
You may qualify for this study if you meet the following criteria:
- You must be 18 years and older.
- You must have at least 1-year history of migraine (with or without aura) including the following:
* Age of onset of migraines prior to 50 years of age.
* Migraine attacks, on average, lasting 4 - 72 hours if untreated.
* 2 -8 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the screening visit.
* Ability to distinguish migraine attacks from tension/cluster headaches.
- The migraine study clinicians will assess your medical and migraine history to determine your eligibility.
You may receive
If you qulify for the study you may receive:
- Study-related evaluations of your migraine-related symptoms and overall health.*
- Investigational drug and study-related care at no cost.
- You may receive compensation for your participation.
*You do not need insurance to participate.